300791.SZ(300791.SZ)

$15.89—

Chart

300791.SZ(300791.SZ)

SHZ

$15.89—

Chart Studio

300791.SZ(300791.SZ)

300791.SZ

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

7/8/26

SIRIO PHARMA (300791.SZ)

Wednesday

7:08 AM

Thesis: Recent declines in net income and operating margins have raised concerns about the company's ability to sustain profitability amidst rising costs and competitive pressures.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$4.3B	$4.6B	$5.2B
Rev. Growth	+1.2%	+8.8%	+12.1%
EPS	$0.45	$1.14	$1.47
EPS Growth	-57.9%	+154%	+28.7%
P/E (fwd)	35.3×	13.9×	10.8×

★ Analysts see FY2027 revenue reaching $5.2B — +12.1% growth in a single year.

What Could Go Wrong

1A significant increase in raw material costs, particularly for key ingredients, could compress margins by up to 5% in the next quarter.
2Potential regulatory changes could impose stricter guidelines on nutritional claims, impacting product marketing.
3Increasing regulatory scrutiny on health claims and product safety
4Potential shifts in consumer preferences towards alternative health products
5Intensifying competition from both domestic and international brands
6Emergence of private label products that could erode market share
7Moderate debt levels could become a concern if cash flows decline significantly
8Liquidity risks if operating cash flow does not improve

FY2025 Snapshot

Revenue: $4.3B
Rev. Growth: +1.2%
Gross Margin: 30.6%
Op. Margin: 0.2%
Net Margin: 3.2%
Net Income: $137M
NI Growth: -58.0%
EPS: $0.45
1Y Return: -35.0%

300791.SZ Chart

My Notes

"Management acknowledged the challenges posed by increasing input costs and competitive dynamics."
Moat: Sirio Pharma's competitive advantage is moderate, primarily driven by brand loyalty and distribution networks…
Watch: The rise of e-commerce and direct-to-consumer brands poses a substantial threat to traditional retail-focused companies.
value - The company may appeal to value investors looking for recovery potential given its low valuation metrics.
Interest rates impact the company's financing costs and consumer spending behavior.
Watch on earnings: Consumer sentiment (UMCSENT), Retail sales growth (RSXFS), Raw material price indices (e.g., corn, soybeans).

One Sentence Summary:

The bear case: a significant increase in raw material costs, particularly for key ingredients, could compress margins by up to 5% in the next quarter.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

P/E (fwd)

35.3×

13.9×

10.8×

What Could Go Wrong

1A significant increase in raw material costs, particularly for key ingredients, could compress margins by up to 5% in the next quarter.

2Potential regulatory changes could impose stricter guidelines on nutritional claims, impacting product marketing.

3Increasing regulatory scrutiny on health claims and product safety

4Potential shifts in consumer preferences towards alternative health products

5Intensifying competition from both domestic and international brands

6Emergence of private label products that could erode market share

7Moderate debt levels could become a concern if cash flows decline significantly

8Liquidity risks if operating cash flow does not improve

My Notes

"Management acknowledged the challenges posed by increasing input costs and competitive dynamics."

Moat: Sirio Pharma's competitive advantage is moderate, primarily driven by brand loyalty and distribution networks…

Watch: The rise of e-commerce and direct-to-consumer brands poses a substantial threat to traditional retail-focused companies.

value - The company may appeal to value investors looking for recovery potential given its low valuation metrics.

Interest rates impact the company's financing costs and consumer spending behavior.

Watch on earnings: Consumer sentiment (UMCSENT), Retail sales growth (RSXFS), Raw material price indices (e.g., corn, soybeans).